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Abstract: PURPOSE Neurocognitive changes are well described after prophylactic or therapeutic whole-
brain radiotherapy (WBRT) and have been reported as early as 3 months after radiotherapy (RT).
Therefore, WBRT with protection of the hippocampal region (hippocampal avoidance, HA) has been
proposed to preserve neurocognition. Our aim was to compare the risk of leukoencephalopathy after
prophylactic cranial irradiation (PCI) with or without HA. METHODS Patients with small-cell lung
cancer who received either lateral-opposed field PCI (non-HA-PCI; n = 9) or hippocampus avoidance
PCI (HA-PCI; n = 9) with available magnetic resonance imaging (MRI) follow-up were identified and
age matched. Pre-therapeutic and follow-up MRI after RT was analysed for leukoencephalopathy based
on the Fazekas score. Bilateral cortical and subcortical brain structures were segmented and analysed
for alterations in dosimetric parameters and volumes. RESULTS There was no significant difference of
Fazekas scores between groups at baseline. Fazekas score differed in post-treatment with a median of 1
in the HA-PCI group and 2 in the non-HA-PCI group (p = 0.007). Significant increase of Fazekas score
over time after RT was observed for HA-PCI patients (p = 0.001) but not for non-HA-PCI patients.
Dmax (highest radiation dose) and brain volume receiving doses >25Gy were higher in HA-PCI patients.
There were no significant volumetric differences for segmented brain structures between groups. CON-
CLUSION Radiological changes are more prominent after HA-PCI than after non-HA-PCI. Although
no standardised neurocognitive testing was performed, the significantly increased Fazekas scores after
HA-PCI are expected to interfere with neurocognitive function. Prospective long-term neurocognitive
studies are warranted before HA-PCI is implemented in routine clinical practice.
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Neurocognitive changes are well described after prophylactic or therapeutic whole brain 
radiotherapy (WBRT) and have been reported as early as 3 months post RT. Therefore WBRT 
with protection of the hippocampal region (hippocampal avoidance, HA) has been proposed 
to preserve neurocognition. Our aim was to compare the risk of leukencephalopathy after 
prophylactic cranial irradiation (PCI) with or without HA. 
Methods 
Patients with small cell lung cancer who received either lateral-opposed field PCI (non-HA-
PCI; n=9) or hippocampus avoidance PCI (HA-PCI; n=9) with available MRI follow-up were 
identified and age matched. Pre-therapeutic and follow-up MRI after RT were analyzed for 
leukencephalopathy based on the Fazekas score. Bilateral cortical and subcortical brain 
structures were segmented and analyzed for alterations in dosimetric parameters and 
volumes. 
Results 
There was no significant difference of Fazekas scores between groups at baseline. Fazekas 
score differed in post-treatment with a median of 1 in the HA-PCI group and 2 in the non-HA-
PCI group (p=0.007). Significant increase of Fazekas score over time after RT was observed 
for HA-PCI patients (p=0.001), but not in the non-HA-PCI patients. Dmax (highest radiation 
dose) and brain volume receiving doses >25Gy were higher in HA-PCI patients. There were 
no significant volumetric differences for segmented brain structures between groups.  
Conclusion 
Radiological changes are more prominent after HA-PCI than after non-HA-PCI. Although no 
standardized neurocognitive testing was performed, the significantly increased Fazekas 
scores after HA-PCI are expected to interfere with neurocognitive function. Prospective long-






Prophylactic cranial irradiation (PCI) is the standard of care in limited and extensive stage 
small cell lung cancer (SCLC), a disease with a high propensity of metastatic spread to the 
brain. PCI reduces the occurrence of brain metastases and increases overall survival (OS)  
(Aupérin et al. 1999; Slotman et al. 2007), although this has been challenged recently by a 
Japanese trial for extensive disease SCLC (Takahashi et al. 2017). Nevertheless, this OS 
advantage comes at a price.  
Irradiation of the brain is associated with a dose-dependent induction of leukencephalopathy 
described already very early in the history of WBRT (Sheline, Wara, and Smith 1980). Patients 
affected by leukencephalopathy may develop some degree cognitive deficits affecting key 
brain functions such as memory, executive function, attention and concentration as well as  
learning disorders, dementia and gait disturbances(Bompaire et al. 2018; Soussain et al. 
2009). The pathophysiology mediating this syndrome is thought to involve demyelination, 
vascular compromise, and direct damage to neurons. 
Apart from leukencephalopathy, hippocampal neural stem-cell injury during WBRT is assumed 
to play a crucial role for memory decline. Therefore, intensity-modulated radiotherapy (IMRT) 
and volumetric modulated radiotherapy (VMAT) were implemented to avoid the hippocampal 
neural stem-cell compartment during WBRT (hippocampal avoidance whole-brain irradiation, 
HA-WBRT). 
Whether this approach actually reduces the occurrence of radiation-induced 
leukencephalopathy or potentially even exacerbates this process through dose maxima in the 
areas surrounding the hippocampus remains unclear. 
To address this question, we compared brain MRI scans of patients treated with hippocampus 
avoidance PCI (HA-PCI) after its introduction in 2015 in our department to patients’ MRI scans 






Material and methods 
Patient cohort: 
All SCLC patients treated with PCI at our institution from 2013 to 2018 (n= 40) were identified 
using Eclipse Data query (Varian Inc, Palo Alto, CA, USA). Only patients with MRI at baseline 
and at least one follow-up MRI were selected for final analyses, leaving 9 patients without and 
17 patients with HA-PCI for the overall analyses for leukencephalopathy scoring (Table 1). To 
account for confounding HA-PCI and non-HA-PCI patients were separately analysed after 
matching based on age, leaving nine patients in each group. 
HA-PCI was introduced in our institution in 2015, while non-HA-PCI was applied from 2011 to 
2015. Patients’ characteristics were evaluated, including ECOG, tumor stage and regimen of 
initial chemotherapy from the institutional database. The study was approved by the Local 
Ethics Commission of the Medial Faculty of the University of Zurich, University Hospital Zurich 
(BASEC-Nr. 2018-01794). 
Treatment and volume delineation: 
For all patients treated with HA-PCI, hippocampal contouring required a three-dimensional 
spoiled gradient echo: a magnetization-prepared rapid gradient echo axial MRI scan of the 
brain with an axial slice thickness ≤ 1.5 mm, fused to a RT-planning head computed tomography 
(CT) scan with an axial slice thickness ≤ 2.0 mm. Bilateral hippocampal contours were manually 
delineated, based on the Contouring Atlas for RTOG 0933 on the fused MRI-CT image set and 
expanded by 5 mm to generate HA regions(Hippocampal Contouring: A Contouring Atlas for 
RTOG 2016). Clinical target volume (CTV) was defined as the whole brain parenchyma. The 
planning target volume (PTV) was defined as the CTV excluding the HA regions plus a 3 mm 
isotropic margin. Dose prescription for prohpylactic cranial irradiation was 10 times 2.5 Gy. All 
plans were normalized to 92 % of the PTV covered by 25 Gy. The minimal dose to the 
hippocampus, defined as D100% of the hippocampus, was not allowed to exceed 9 Gy, and 
the maximum hippocampal dose was not being allowed to exceed 16 Gy; D100% of the 
hippocampus exceeding 10 Gy and maximum hippocampal doses exceeding 17 Gy were 
considered as unacceptable deviations and required re-planning before treatment initiation 
(Gondi et al. 2014). 
For HA planning purposes automated treatment planning module, AutoPlanning (AP), 
included in Pinnacle 14.0 (Philips Radiation Oncology Systems, Fitchburg, WI) was used for 
plan optimization. The model used for optimization was developed to provide an improved 
dose distribution within the PTV with significantly reduced Dmax (Krayenbuehl et al. 2017) 
and has been adapted for a dose fractionation of 10 x 2.5 Gy instead of 10 x 3 Gy. Only the 
constraints on the PTV were changed, beam geometry and organ at risk objectives remained 
unchanged. 
For the non-HA-PCI group lateral opposed fields were used with individual Multileaf collimation 
MLC shielding adapted to the PTV Plans were normalized to a dose point located in the PTV. 
The dose point had to be set in such a way that 95% of the PTV had to be covered by at least 
95% and the maximal point dose had to be kept below 110% of the prescribed dose. However, 
for non-HA-PCI no constraints were set for avoiding the hippocampal regions. 
Leukencephalopathy scoring 
Pre-therapeutic MRI and regular follow-up MRI starting on average 7 months (±6) after RT 
were analyzed. Based on the Fazekas classification, the degree of leukencephalopathy was 
scored on T2-FLAIR MRIs in all patients independently and blinded by one neuroradiologist 
(XX) and two radiation oncologists (YY, ZZ); where the three physicians disagreed a 
consensus was reached (Fazekas et al. 1987). 
Leukencephalopathy or its radiological correlate in forms of white matter hyperintensities or 
white matter lesions can be divided into periventricular and deep white matter lesions. The 
distinction is made on base of visual rating scales, whereas histopathology and aetiology 
between these two classes seems to be different (K. W. Kim, MacFall, and Payne 2008; 
Debette and Markus 2010). We focused on periventricular white matter hyperintensity as high 
periventricular white matter lesion load is the predominantly observed pattern of white matter 
change after WBRT and may be associated with reduced cognitive function (Griffanti et al. 
2018; Monaco et al. 2013). Periventricular Fazekas classification describes the different types 
of hyperintense signal abnormalities surrounding the ventricles. Periventricular hyperintensity 
(PVH) was rated as 0 = absence, 1 = “caps” or pencil-thin lining, 2 = smooth “halo,” 3 = irregular 
PVH extending into the deep white matter. It relates to a combination of demyelination, and 
subependymal gliosis, as well as small vessel ischemia (K. W. Kim, MacFall, and Payne 2008; 
Wardlaw, Valdés Hernández, and Muñoz-Maniega 2015). 
 
Analysis of RT dose-volume relations 
Dose volume histograms (DVHs) were exported in text format using Eclipse Treatment 
Planning System (Version 13.0, VARIAN, Palo Alto, USA), imported into R (Version 3.3.2., R 
Foundation for Statistical Computing, Vienna, Austria) and processed using DVH metrics 
library (https:// cran.r-project.org/web/packages/DVHmetrics/index.html) to generate dose 
volumes and dose volume histograms. DVH metrics were further analyzed using a paired 
Wilcoxon rank-sum test for statistical testing (GraphPad Prism version 6.00, GraphPad 
Software, San Diego, California, USA). Dosimetric parameters for brain parenchyma, 
including Dmax, Dmean, V26 Gy and V25 Gy, were analyzed.  A p-value below 0.05 was 
considered as statistically significant.  
Analysis of volumetric alterations 
The scanning protocol included a T1-weighted 3D magnetization rapid-acquisition gradient 
echo (MP-RAGE) acquired in an axial orientation. MRI data sets were examined for image 
quality. The T1-weighted images were transformed from the DICOM to NRRD file format by 
creating a nhdr header file for each subject. Cortical thickness analysis was performed using 
FreeSurfer version 5.3 (Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, 
MA, USA). Cortical reconstruction and volumetric segmentation were performed with the 
FreeSurfer image analysis suite (http://surfer.nmr.mgh.harvard.edu/)(B. Fischl, Sereno, and 
Dale 1999; Bruce Fischl et al. 1999). The images were aligned to a common atlas and 
grayscale intensity was normalized and corrected for inhomogeneity of the magnetic field. All 
voxels were labeled as gray matter, white matter or cerebral spinal fluid and the gray matter 
surface (pial) and white matter surface were created. The deep grey matter in each 
hemisphere was segmented into seven subcortical structures: caudate nucleus (CN), 
putamen (PT), globus pallidus (GP), thalamus (TH), hippocampus, amygdala and nucleus 
accumbens. For each subcortical structure the respective volume was calculated. Cortical 
surfaces were parcellated into discrete units based on gyral and sulcal anatomy. All processed 
images were visually inspected for topological defects, geometric inaccuracies due to brain 
lesions and other defects. A list of structures analyzed with significant volumetric differences 
is provided in Table 2 and an example figure of analyzed areas in Figure 1. Bonferroni 
correction was applied to correct for multiple testing.  
 
Results 
Patient characteristics are depicted in Table 1. The median age of participants in the non-HA-
PCI group was 57 (±5) years and 68 (±7) years in the matched HA-PCI group (p = 0.3). Overall, 
median age of all 17 HA-PCI patients was 70 (±8) years. Median MRI follow up was 7 months 
in all groups. Age matching was performed to control for age as a potential confounding factor 
for the development for leukencephalopathy. 
There was no significant difference in Fazekas score between groups prior to RT (p = 0.28 
Figure 2). The median change of Fazekas score from pre to post treatment was 0 (mean: 0.2) 
for the non-HA-PCI group and 1 (mean: 1.1) for the HA-PCI group (p = 0.002; Figures 2, 3). 
The Fazekas score differed between the two groups at first follow-up (median: 6 months post 
treatment): in the HA-PCI group, the median value of the Fazekas score was 2 versus 1 in the 
non-HA-PCI group (p = 0.007). Furthermore, a significant increase of the Fazekas score at 
follow-up MRI after RT was observed in the HA group comparing pre- and post-treatment 
MRIs (p = 0.001). There was no significant difference comparing pre- and post-treatment MRIs 
in patients treated with non-HA-PCI. 
Significant differences amongst dosimetric parameters and hippocampal/cerebellar volumes 
are listed in Table 3. Details for all volumetric parameters are provided in the supplementary 
appendix. Median Dmax was higher in the HA-PCI compared to the non-HA-PCI group (28.2 
Gy ± 0.4 vs. 27.0 Gy ± 1.5; p = 0.002). V26 Gy also showed higher values in the HA-PCI 
compared to the non-HA-PCI group (12.2 % ± 38.2 vs. 2.7 % ± 4.9; p = 0.03). There were no 









This study reports increased leukencephalopathy after HA-PCI compared to non-HA-PCI 
during follow-up: in the HA group, the median value of the Fazekas classification amounted to 
2 (range 1-3) versus 1 (range 1-2) in the non-HA-PCI group (Figure 3). The significant increase 
of the Fazekas classification from pre- to post treatment MRIs reported in this study represents 
the first evidence of a greater risk of leukencephalopathy after HA-PCI compared to non-HA-
PCI. There were no significant volumetric differences for segmented brain structures between 
groups. 
Previous reports have shown increased leukencephalopathy after whole brain irradiation 
either in a prophylactic or a definitive intention (Frytak et al. 1989; Monaco et al. 2013). Corn 
et al. described a dose-dependence of leukencephalopathy after WBRT (Corn et al. 1994). In 
our study, HA-PCI patients received a significantly higher V26/V25 Gy with increased dose 
maxima compared to conventionally treated PCI patients in the white matter (Table 3). This is 
also reported in studies with therapeutic HA-WBRT: sparing of the hippocampi comes at the 
cost of higher mean and maximum brain doses (Gondi et al. 2014).Similar imaging changes 
in white matter have been linked to neurocognitive dysfunction and decline in several 
neurocognitive disorders (Fazekas et al. 1987; O’Sullivan et al. 2001; Kondziolka et al. 2005). 
Moreover, periventricular white matter hyperintensity seems to play an more important role 
with regard to neurocognition decline than deep white matter hyperintensity does (Griffanti et 
al. 2018). In an MRI study periventricular white matter hyperintensities volume paralleled the 
decline in mental processing speed, whilst neither presence nor progression of deep white 
matter hyperintensity was associated with changes in any of the used cognitive tests (van den 
Heuvel et al. 2006). Therefore, we consider these observed changes clinically significant, 
although our patients were not tested for neurocognitive function.  
To date, radiation to the whole brain is still the guideline recommended treatment modality in 
prophylactic intention for limited and extensive disease SCLC or the definitive treatment in the 
presence of multiple brain metastases of all cancer types (NCCN Guidelines for Small Cell 
Lung Cancer 2017; Brown et al. 2018).  
However, neurocognitive impairment mainly measured at 4 months post-RT is of concern and 
several possibilities for preservation of neurocognition have been investigated. Gondi et al. 
found that HA-WBRT is associated with significant memory preservation compared with a 
prespecified historical control (Gondi et al. 2014). Brown et al. found that memantine reduces 
the rate of decline in memory, executive function, and processing speed after WBRT (Brown 
et al. 2013). Therefore, the introduction of HA-WBRT, as well as the use of concomitant 
memantine are considered possible options to prevent or at least alleviate these 
neurocognitive changes. As there is a low risk of hippocampal failures, HA-WBRT appears to 
be safe (Gondi et al. 2010). Redmond et al. suggest a potential benefit of HA in limiting the 
neuropsychological sequelae of brain radiation, but with a risk of failures in the spared region 
(Redmond et al. 2017).   
The RTOG-0933 was the first prospective evidence that HA-WBRT leads to significant 
preservation of neurocognition (Gondi et al. 2014). Recently, the prospective randomized NRG 
Oncology CC001 study confirmed that conformal avoidance of the hippocampal 
neuroregenerative stem cell niche during WBRT preserves neurocognitive function while 
achieving similar intracranial control and survival.  
In contrast, we observed that, despite significantly improved homogenized dose distributions 
with considerably fewer high dose areas compared to the planning guidelines of RTOG-0933, 
patients with HA- PCI developed leukencephalopathy strikingly more frequently and more 
pronounced as detected by serial follow-up cMRI than patients receiving lateral-opposed field 
PCI. 
 Several trials on HA-PCI are currently conducted (listed in Table 4). Despite the encouraging 
results, long-term outcome of HA-WBRT has not been studied so far and one concern is that 
cortical dose – which is higher in HA-WBRT - may be more relevant for long-term 
neurocognitive functioning. This concern was corroborated in light of the results of 
NCT01780675 presented at ESTRO 2019. In the not yet fully published study Belberdos et al. 
investigated hippocampus-dependent memory functioning and safety after PCI with or without 
hippocampus sparing in SCLC patients (Belderbos et al. 2019). This randomized study 
recruited 168 patients and neurocognitive testing included the Hopkins Verbal Learning Test-
Revised (HVLT-R). Neurocognitive functioning was assessed at 6 different time points until 24 
months after irradiation. A neurocognitive decline was observed after treatment. However, 
without a significant difference between the two arms. Furthermore, the incidence of brain 
recurrences was not increased in the hippocampus avoidance region, whilst this issue was of 
great concern and debate after retrospective series showed such an increase in their cohorts 
(Korkmaz Kirakli and Oztekin 2017). Recurrence rates generally vary and are lower than 5% 
in the hippocampus regions (Y. Kim et al. 2019; Sun et al. 2016). We did not observe higher 
recurrence rates in our data, but this was not quantified as this was not the purpose of our 
study. 
The findings of our study urgently need to be validated in independent patient cohorts, ideally 
from prospective trials, and correlated with neurocognitive function tests, as HA-WBRT and 
HA-PCI are already being implemented into clinical routine after the positive results of RTOG-
0933 and 0614 for the early neuro-cognitive endpoints. 
Whether this leads to a better preservation of neurocognitive function or might even be 
associated with an increased risk of late side effects should be further investigated in 
longitudinal studies. Our results also suggest that the dose response for white matter changes 
may be very steep, as we already employed an automated HA-PCI planning technique 
implementing harder constraints for the maximally allowed brain dose compared to the RTOG-
0933 planning criteria and still saw these significant changes for PCI patients receiving brain 
doses of less than 30 Gy. 
Limitations of this study include its retrospective nature and the small sample size, particularly 
for the non-HA PCI group. This study did also not incorporate covariates such as use of 
chemotherapy in the analysis; still, both groups received similar regimens and no difference 
in the use of chemotherapy was observed. However, this study’s strength is that pre- and post-
treatment MRI scans were available: regular MRI follow-up is not standard of care, but has 




Although the RTOG 0933 trial reported preservation of short-term neurocognitive function by 
HA-WBRT, our results suggest that long-term radiological changes are more pronounced after 
HA-PCI than after non-HA-PCI. While no neurocognitive testing was performed in our patients, 
the increased Fazekas score after HA-WBRT is indicative of potential negative long-term 
effects. Long-term neurocognitive investigation from prospective studies should be performed 





Figure 1: An example of the segmented structures 
 
Figure 2: Fazekas score for the individual subjects in the non-HA-PCI and HA-PCI groups at 
first follow-up and pre-treatment.  
 
 Figure 3: Average Fazekas score for the non-HA-PCI and HA-PCI groups at follow up post 
treatment with the error bars representing the mean and +/- standard deviation.  
฀= Matched Patients; ฀ = unmatched patients   
 
Figure 4: T2-Flair of a patient prior HA-PCI (1/2A) and after (1/2B) and to the brain. 2A shows 
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Table 1 Patient characteristics. 
 Prophylactic 
cranial irradiation 






irradiation (age matched) 
Number n = 9 N = 17 n = 9 
median Age (range) 57 years (54 – 69) 70 years (51–84) 64 years (51–71) 
Sex    
Male 7 12 6 
Female 2 5 3 
ECOG    
0-1 3 15 7 
2 6 2 2 
Disease Stage    
Limited 5 5 3 
Extensive 4 12 6 
Response to initial chemotherapy  
complete 2 2 2 
partial 7 14 7 
minor 0 1 0 
Total number of cycles of initial chemotherapy  
one 0 1 0 
three 0 1 0 
four 5 6 4 
five 0 2 2 
six 4 7 3 
Regimen of initial chemotherapy  
Carboplatin / 
Etoposide 
5 11 5 
Cisplatin / Etoposide 4 5 4 
median MRI follow-up 
in month (range) 
7 (2 – 14) 7 (2 – 11) 7 (2 – 11) 
 
  
Table 2: Volumes of segmented cerebral structures (in mm3) 
Cerebral structure No HC HCS p-value 
Left - Lateral - Ventricle 13454.3 (±14453.4) 18467.4 (±8351.8) 0.94 
Left - Inf - Lateral - 
Ventricle 
453.5 (±682.1) 922.2 (±366.3) 0.31 
Left - Cerebellum - WM 12478.9 (±2754.6) 13542.8 (±3657.7) 0.44 
Left - Cerebellum - 
Cortex 
51047.4 (±6465.8) 48690.8 (±4425.0) 0.65 
Left - Caudate 2847 (±789.1) 3089.3 (±387.2) 0.81 
Left - Putamen 4368.2 (±694.4) 3885.2 (±596.8) 0.56 
Left - Pallidum 1758 (±246.1) 1744 (±289.9) 0.28 
3rd - Ventricle 1555.3 (±814.0) 2097.8 (±521.4) 0.19 
Brain - Stem 19498.7 (±4052.0) 20382.1 (±1753.0) 0.73 
Left - Hippocampus 3802.9 (±395.7) 3913.9 (±352.4) 0.18 
Left - Amygdala 1445.8 (±299.7) 1398.3 (±58.9) 0.69 
CSF 1156.3 (±913.0) 1100.2 (±193.2) 0.29 
Left - Accumbens - 
area 
380.3 (±102.6) 398.4 (±117.2) 0.93 
Left - Ventral DC 4294.7 (±621.1) 4137 (±382.3 0.97 
Left - choroid - plexus 854.5 (±359.5) 818 (±260.5) 0.40 
Right - Lateral - 
Ventricle 
11840.6 (±14863.7) 14012 (±5724.3) 0.63 
Right – Inf – Lateral - 
Ventricle 
692.7 (±432.7) 817.9 (±550.4) 0.31 
Right - Cerebellum - 
WM 
14566.1 (±3264.2) 12753.9 (±2802.0) 0.35 
Right - Cerebellum - 
Cortex 
52821.2 (±6460.2) 49448 (±3166.9) 0.34 
Right - Thalamus 6780.1 (±965.0) 6595.1 (±838.8) 0.30 
Right - Caudate 3333.3 (±744.3) 3246.6 (±338.5) 0.38 
Right - Pallidum 1579.9 (±271.7) 1735.6 (±305.2) 0.88 
Right - Accumbens - 
area 
428.9 (±109.9) 398.6 (±65.3) 0.41 
Right - Ventral DC 4073.2 (±680.4) 4105 (±351.9) 0.91 
Right -Hippocampus 4001.5  (±485.1) 41338 (±509.2) 0.54 
Optic - Chiasm 226.9 (±91.4) 247.3 (±67.0) 0.71 
CC_Posterior 971 (±429.4) 897.9 (±207.2) 0.07 
CC_Mid_Anterior 514 (±128.0) 476.4 (±110.1) 0.66 
CC_Anterior 857.6 (±250.5) 829.8 (±196.0) 0.13 
  
CC - corpus callosum; CSF - cerebrospinal fluid; DC - diencephalon; Inf - inferior; WM - white matter 
 
  
Table 3 Differences amongst total brain dose and volumetric parameters. 
Median Doses total brain non-HA-PCI HA-PCI p-value 
Dmax  26.5 Gy (± 1.5) 28.2 Gy (± 0.4)   0.002 
Dmean  25.0 Gy (± 0.8) 25.0 Gy (± 0.3) 0.11 
V26 Gy 2.2 % (± 4.9) 12.2 % (± 38.2) 0.03 
V25 Gy 47.3 % (± 21.4) 68.5 % (± 17.5) 0.02 
Cortical structure volumes   
Left - Hippocampus 3802,9 (±395,7) 3913,9 (±352,4) 0.456 
Right -Hippocampus  4001.5 (±485.1) 41338 (±509.2) 0.51 
Left Cerebellum   63526.3 (±9220.4) 62233.6 (±8082.7) 0.54 
Right Cerebellum  67387.3 (±9724.2) 62201.9 (±5968.9) 0.35 
 
  
Table 4: Trials on HA-PCI currently conducted: 
Trial PI Projected 
Participants 
Arms/Intervention Primary Endpoint Secondary Endpoint Status 
NCT02635009    




Irradiation 3D RT vs 
Hippocampal Avoidance 
PCIusing IMRT  





using the Reliable 




Events, Intracranial relapse 
rate, OS, HRQoL, Preservation 
of neurocognitive function, 





M.D. Johns Hopkins 
University 
125 
Hippocampal sparing PCI 
in SCLC 
Performance on the 
HVLT-R at 6 month 
in comparison to 
historical control 
group (RTOG 0212) 
HVLT-R at 12 month in 
comparison to historical 
control group (RTOG 0212), 
cognitive function, QoL, HC 
brain metastasis, 
leptomeningeal 













10 times 2.5 Gy (total 25 
Gy) 
Neurocognitive 
decline as primary 
outcome measure 
recorded by recall 
score at 4 months 




Ming Chen, PHD 
Zhejiang Cancer 
Hospital   
 













Learning Test as 
primary outcome 
measure 
OS, hippocampus metastasis 
and image changes of brain 
as secondary outcome 
measure 
Recruiting 








concomitant to the 
second cycle of CHT and 










(COWAT) and Trail 
Making Test Part A 
and B (TMT A/B) 
BMFS, Adverse events, 
neurotoxicity, individual tests 
for each cognitive domain, 




Núria Rodríguez de 
Dios, MD PhD 
 
Hospital de la 
Esperanza. 
Department of 











(Free and Cued 
Selective Reminding 
Test) 3 months after 
radiation 
Neurocognitive functioning 
(NCF) 6, 12, 24 months after 
radiation, Hippocampus brain 
metastases, Hippocampus 
volume, Adverse effects and 








Irradiation (WBRT) with 
reduced dose to the 
hippocampi of patients 
with histologically 
confirmed LD SCLC and 
complete response (CR) of 




(number of patients 
that complete 
neuro-cognitive and 
clinical follow up 
after WBRT with HC 
sparing) 
neurocognitive testing, QOL, 
changes in serum markers for 
neuronal damage, changes in 
imaging biomarkers (TRAM) 
and neurocognitive tests 
score 
unknown 
 
